LoginRegister
    Novartis, Lonza strengthen biosimilars push with MS, arthritis drug dealsNovartis, Lonza strengthen biosimilars push with MS, arthritis drug deals
    Roche Xofluza shows promise in reducing risk of developing flu by 86pcRoche Xofluza shows promise in reducing risk of developing flu by 86pc
    China expansion of drug bulk-buy programme puts pressure on pharma companiesChina expansion of drug bulk-buy programme puts pressure on pharma companies
    Sanofi revival depends on outsider with nose for big drugs: ReportSanofi revival depends on outsider with nose for big drugs: Report
    DOP junks Cipla plea to refix MRP of Tafmune–EMDOP junks Cipla plea to refix MRP of Tafmune–EM
    Government Panel refuses to exempt Next Gen DES from price capGovernment Panel refuses to exempt Next Gen DES from price cap
    Fund Diversion Case: SEBI restricts Transgene Biotek, 6 others from securities marketFund Diversion Case: SEBI restricts Transgene Biotek, 6 others from securities market
    NovaLead Pharma topical drug Galnobax for Diabetic Foot Ulcer proceeds for phase 3 trialNovaLead Pharma topical drug Galnobax for Diabetic Foot Ulcer proceeds for phase 3 trial
    Amgen challenges Alexion Pharma blood disorder treatment Soliris in US patent courtAmgen challenges Alexion Pharma blood disorder treatment Soliris in US patent court
    4WEB Medical gets USFDA clearance for cervical stand-alone interbody fusion device4WEB Medical gets USFDA clearance for cervical stand-alone interbody fusion device
    Kyowa Kirin gets USFDA approval for Nourianz tablets to treat adults with Parkinsons diseaseKyowa Kirin gets USFDA approval for Nourianz tablets to treat adults with Parkinsons disease
    Delhi HC given Green Signal to Natco Pharma for generic of Novartis cancer drug CeritinibDelhi HC given Green Signal to Natco Pharma for generic of Novartis cancer drug Ceritinib
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X